Screening eligibility would increase overall and among those with prediabetes with USPSTF 2021, ADA 2022 guidelines
WEDNESDAY, May 18, 2022 (HealthDay News) — Implementing the new changes in U.S. Preventive Services Task Force (USPSTF) and American Diabetes Association (ADA) diabetes screening guidelines would increase screening eligibility among U.S. adults, according to a research letter published in the May 17 issue of the Journal of the American Medical Association.
Michael Fang, Ph.D., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues used data from the 2015 to 2020 National Health and Nutrition Examination Survey to estimate the proportion of asymptomatic U.S. adults eligible for screening based on new versus current USPSTF and ADA guidelines.
Data were included for 4,480 adults. The researchers observed increases in the weighted proportion eligible for screening from 36.3 to 43.0 percent when comparing USPSTF 2015 and 2021 guidelines, and from 76.7 to 82.9 percent when comparing ADA 2003 and 2022 guidelines. Among those with prediabetes, screening eligibility increased from 50.1 to 56.2 percent when comparing USPSTF 2015 with 2021, and from 89.4 to 93.7 percent when comparing ADA 2003 to 2022. Among those with undiagnosed diabetes, screening eligibility increased from 58.7 to 67.8 percent when comparing USPSTF 2015 to 2022, but it stayed stable (97.6 to 99.1 percent) when comparing ADA 2003 with 2022 guidelines.
“The ADA 2022 guideline identifies a larger portion of persons with prediabetes or diabetes compared with the USPSTF 2021 guideline but requires screening approximately twice as many people,” the authors write.
Abstract/Full Text (subscription or payment may be required)
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer
Pregnancy Complications Linked to Subsequent Risk for Cardiometabolic-Renal Conditions
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis